Cansino Biologics
Cansino Biologics Inc., commonly referred to as Cansino, is a prominent biopharmaceutical company headquartered in China (CN). Founded in 2009, the company has established itself as a leader in the development of innovative vaccines and biologics, with a strong focus on addressing global health challenges. Cansino operates primarily in the fields of vaccine research and development, particularly in the areas of infectious diseases and oncology. The company gained significant recognition for its pioneering work on the Ad5-nCoV vaccine, which was one of the first COVID-19 vaccines to receive emergency use authorisation. Cansino's unique adenoviral vector platform sets it apart in the industry, enabling rapid development and deployment of vaccines. With a robust pipeline and strategic partnerships, Cansino Biologics continues to solidify its position as a key player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Cansino Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cansino Biologics's score of 32 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cansino Biologics's reported carbon emissions
In 2023, Cansino Biologics reported total carbon emissions of approximately 37,294,900 kg CO2e, comprising 2,335,900 kg CO2e from Scope 1 and 19,689,150 kg CO2e from Scope 2 emissions. The company has shown a significant reduction in emissions over the years, with a notable decrease from 35,159,360 kg CO2e in 2021 to the current figure. In 2022, their emissions were about 30,517,250 kg CO2e, while in 2021, they reached approximately 35,159,360 kg CO2e. The emissions from Scope 1 in 2022 were around 30,517,250 kg CO2e, and Scope 2 emissions were about 18,030,930 kg CO2e. Cansino Biologics has not disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or any formal climate pledges. However, the company continues to monitor and report its emissions, indicating a commitment to transparency in its climate impact. Overall, Cansino Biologics is actively engaged in tracking its carbon footprint, with a focus on reducing emissions across its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 4,609,750 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 10,386,950 | 000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000 | 000 | 00,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cansino Biologics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
